Director/PDMR Shareholding

RNS Number : 0163G

e-Therapeutics plc

23 May 2017

 



E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Oxford, UK, 23 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it received notification on 22 May 2017 from one of its directors, Trevor Jones, that he had purchased 59,400 shares in the Company at a price of 8.25 pence per share. This purchase took place on 12 May 2017. His resultant holding in the Company is now 166,897 shares representing 0.06 per cent. of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Trevor Mervyn Jones
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	e-Therapeutics plc
b)	LEI	21380049RHSSJXWKYT18
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1 pence ISIN:   GB00B2823H99
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	59,400 ordinary shares at a price of 8.25 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	12 May 2017
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

For further information, please contact:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Alex Shaw	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

DSHLLFLEEVIVFID